Determination of melphalan in human plasma by UPLC–UV method
- 37 Downloads
It is desirable to develop a fast method for quantification of melphalan due to its instability. Here we report a method for quantification of melphalan (MPL) in human plasma using a UPLC–PDA system. Briefly, 50 µL plasma sample was mixed with 25 µL internal standard (2500 ng/mL acetylmelphalan in methanol) and 25 µL 20% trichloroacetic acid, and centrifuged at 21,000 g (15,000 rpm) at 4 °C for 3 min. The supernatant (5 µL) was injected onto an Acquity™ BEH C18 LC column (2.1 × 50 mm, 1.7 µm) and eluted with 25 mM NH4AC (pH 4.7)—acetonitrile in a gradient mode at a flow rate of 0.6 mL/min. The column kept at 40 ± 5 °C and the autosampler kept at 4 ± 5 °C. The detector set at 261 nm, and sampling rate was 40points/sec. The retention times were typically 2.11 min for melphalan and 2.38 min for the internal standard. Total run time is 4 min per sample. Calibration range was 100–40,000 ng/mL. The lower limit of quantification was 100 ng/mL. The method was validated based on the FDA guidelines, and applied to a clinical pharmacokinetic study in pediatric patients.
KeywordsMelphalan UPLC–UV Plasma Pediatric Pharmacokinetic.
This work was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 RR024131 (a shared instrument award to Dr. Huang) and UCSF-CTSI Grant number KL2 TR000143 (Dr. Long-Boyle). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Krumbhaar EB, Krumbhaar HD (1919) The blood and bone marrow in Yelloe Cross Gas (Mustard Gas) poisoning: changes produced in the bone marrow of fatal cases. J Med Res 40(3):497–508 493Google Scholar
- 18.Clinical Pharmacology Quanlity Assurance (Cpqa) Program. CPQA Guidelines for chromatographic method development and validation based on (and including) FDA guidelines dated May 2001, Version 4.0 (2012). 1–52 (2012)Google Scholar
- 19.Us Department of Health and Human Services, Food and Drug Administration. Guidance for industry: bioanalytical method validation. May 2001Google Scholar
- 20.Sparidans RW, Martens I, Valkenburg-Van Iersel LB, Den Hartigh J, Schellens JH, Beijnen JH (2011) Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 879(21):1851–1856CrossRefGoogle Scholar
- 21.Huang L, Marzan F, Jayewardene AL, Lizak PS, Li X, Aweeka FT (2009) Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 877(3):285–290CrossRefGoogle Scholar